Background Clinical application of implantable cardioverter defibrillator(ICD) can significantly reduce the incidence of sudden cardiac death(SCD). However, ICD cannot prevent ventricular tachycardia(VT) or ventricula...Background Clinical application of implantable cardioverter defibrillator(ICD) can significantly reduce the incidence of sudden cardiac death(SCD). However, ICD cannot prevent ventricular tachycardia(VT) or ventricular fibrillation(VF). Previous studies indicated that ICD combined with reasonable anti-arrhythmic drug therapy can improve anti-arrhythmic effect. EMIAT, CAMIA and OPTIC trials reported that combined treatment of Amiodarone and β receptor blockers was superior to their treatment alone. Therefore, it is necessary to give anti-arrhythmic treatment after ICD implantation. Methods Totally 180 ICD implantation recipients enrolled in our hospital from Jan 2011 to March 2014. Among them, 39 recipients were treated with Amiodarone(Group A), 89 recipients were treated with β blocker(Group B), and 52 recipients were treated with Amiodarone combined withβ blocker(Group C) after ICD implantation. Patients were followed up for 3 to 40 months by monitoring the heart rate, LVEF Value and rapid ventricular arrhythmias events. Results There were no significant differences on heart rate before and after ICD implantation among the three groups(P = 1.28, P = 0.85), but the change of heart rate was statistically higher(P = 0.04) in Group B compared with Group A and Group C. There were no statistical significance in LVEF value before ICD implantation and after ICD implantation and the change of LVEF value(P = 0.56, P = 0.50, P = 0.99). The occurrence rate of rapid ventricular arrhythmias in Group A(10.26%) and Group B(10.11%) was significantly higher(P = 0.04) than in Group C(1.92%). which wae slightly increased by Amiodarone in Group A and Group C. There were 2 cases of thyroid dysfunction in Group A,1 case in Group C and no case in Group B. No pulmonary interstitial fibrosis cases were found in this study.Conclusions Combined treatment with Amiodarone and β receptor blockers could significantly reduce rapid ventricular arrhythmias when compared with treatment of Amiodarone or β blocker alone.展开更多
Background Non-high-density lipoprotein cholesterol(non-HDL-C) and Apolipoprotein B(apo B) increase cardiovascular disease(CVD) risk, but few studies have explored the correlations of non-HDL-C and apo B with coronary...Background Non-high-density lipoprotein cholesterol(non-HDL-C) and Apolipoprotein B(apo B) increase cardiovascular disease(CVD) risk, but few studies have explored the correlations of non-HDL-C and apo B with coronary atherosclerosis in non-diabetes acute coronary syndrome(ACS). Methods The study enrolled 443 subjects with non-diabetic ACS, and all subject check coronary angiography, and coronary atherosclerosis were evaluated using Gensini Score(GS) scale including small(GS1-15), middle(GS16-43), and severe(GS≥44). All subjects were classified into 4 groups: High apo B(≥90 mg/d L) and High non-HDL-C(≥130 mg/d L), High non-HDL-C alone, High apo B alone, and normal apo B and non-HDL-C. Results After adjusted for risk factors, non-HDL-C and apo B were positively correlated with GS( r = 0.075, P = 0.002 and r = 0.092, P < 0.001). In the GS 0-15,high non-HDL-C + high apo B group 29.3% and high apo B alone group 28.2% were significantly lower than normal non-HDL-C+ normal apo B group 48%(p = 0.010). In the GS 16-43, high non-HDL-C alone group 50.4%and high apo B alone group 47.6% were significantly more than high non-HDL-C+ high apo B group 34.1%(P =0.036). In the GS ≥44, high non-HDL-C+ high apo B group 36.6% was significantly higher than high non-HDLC alone group 16% and normal non-HDL-C+ normal apo B 14.2%(P < 0.001). Conclusions The high non-HDLC and apo B are the risk factors for coronary artery atherosclerosis in non-diabetic ACS.展开更多
基金supported by the Natural Science Foundation of China(No.81070182)the Natural Science Foundation of Guangdong Province(No.10151008901000224)
文摘Background Clinical application of implantable cardioverter defibrillator(ICD) can significantly reduce the incidence of sudden cardiac death(SCD). However, ICD cannot prevent ventricular tachycardia(VT) or ventricular fibrillation(VF). Previous studies indicated that ICD combined with reasonable anti-arrhythmic drug therapy can improve anti-arrhythmic effect. EMIAT, CAMIA and OPTIC trials reported that combined treatment of Amiodarone and β receptor blockers was superior to their treatment alone. Therefore, it is necessary to give anti-arrhythmic treatment after ICD implantation. Methods Totally 180 ICD implantation recipients enrolled in our hospital from Jan 2011 to March 2014. Among them, 39 recipients were treated with Amiodarone(Group A), 89 recipients were treated with β blocker(Group B), and 52 recipients were treated with Amiodarone combined withβ blocker(Group C) after ICD implantation. Patients were followed up for 3 to 40 months by monitoring the heart rate, LVEF Value and rapid ventricular arrhythmias events. Results There were no significant differences on heart rate before and after ICD implantation among the three groups(P = 1.28, P = 0.85), but the change of heart rate was statistically higher(P = 0.04) in Group B compared with Group A and Group C. There were no statistical significance in LVEF value before ICD implantation and after ICD implantation and the change of LVEF value(P = 0.56, P = 0.50, P = 0.99). The occurrence rate of rapid ventricular arrhythmias in Group A(10.26%) and Group B(10.11%) was significantly higher(P = 0.04) than in Group C(1.92%). which wae slightly increased by Amiodarone in Group A and Group C. There were 2 cases of thyroid dysfunction in Group A,1 case in Group C and no case in Group B. No pulmonary interstitial fibrosis cases were found in this study.Conclusions Combined treatment with Amiodarone and β receptor blockers could significantly reduce rapid ventricular arrhythmias when compared with treatment of Amiodarone or β blocker alone.
基金supported by the Natural Science Foundation of China(No.81070182)the Natural Science Foundation of Guangdong Province(No.10151008901000224)
文摘Background Non-high-density lipoprotein cholesterol(non-HDL-C) and Apolipoprotein B(apo B) increase cardiovascular disease(CVD) risk, but few studies have explored the correlations of non-HDL-C and apo B with coronary atherosclerosis in non-diabetes acute coronary syndrome(ACS). Methods The study enrolled 443 subjects with non-diabetic ACS, and all subject check coronary angiography, and coronary atherosclerosis were evaluated using Gensini Score(GS) scale including small(GS1-15), middle(GS16-43), and severe(GS≥44). All subjects were classified into 4 groups: High apo B(≥90 mg/d L) and High non-HDL-C(≥130 mg/d L), High non-HDL-C alone, High apo B alone, and normal apo B and non-HDL-C. Results After adjusted for risk factors, non-HDL-C and apo B were positively correlated with GS( r = 0.075, P = 0.002 and r = 0.092, P < 0.001). In the GS 0-15,high non-HDL-C + high apo B group 29.3% and high apo B alone group 28.2% were significantly lower than normal non-HDL-C+ normal apo B group 48%(p = 0.010). In the GS 16-43, high non-HDL-C alone group 50.4%and high apo B alone group 47.6% were significantly more than high non-HDL-C+ high apo B group 34.1%(P =0.036). In the GS ≥44, high non-HDL-C+ high apo B group 36.6% was significantly higher than high non-HDLC alone group 16% and normal non-HDL-C+ normal apo B 14.2%(P < 0.001). Conclusions The high non-HDLC and apo B are the risk factors for coronary artery atherosclerosis in non-diabetic ACS.
